Abstract
A 25-year-old man with DSM-IV-TR Axis I social phobia and Axis II avoidant personality disorder and erectile dysfunction, presenting with depression, anxiety and insomnia, responded partially to extended release oral venlafaxine (75 mg/die for 6 weeks), but developed side effects and worsening symptoms when dose was increased to 150 mg/die; he responded to a combination of 75 mg/die venlafaxine and 4 mg/die reboxetine and improved on most of his symptoms.
MeSH terms
-
Adult
-
Cyclohexanols / therapeutic use*
-
Drug Therapy, Combination
-
Erectile Dysfunction / complications*
-
Erectile Dysfunction / drug therapy*
-
Humans
-
Male
-
Morpholines / therapeutic use*
-
Personality Disorders / complications*
-
Personality Disorders / drug therapy*
-
Personality Disorders / psychology
-
Phobic Disorders / complications*
-
Phobic Disorders / diagnosis
-
Phobic Disorders / psychology
-
Reboxetine
-
Selective Serotonin Reuptake Inhibitors / therapeutic use*
-
Venlafaxine Hydrochloride
Substances
-
Cyclohexanols
-
Morpholines
-
Serotonin Uptake Inhibitors
-
Venlafaxine Hydrochloride
-
Reboxetine